FOXO4-DRI
FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice.
FOXO4-DRI: FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice. FOXO4-DRI is a senolytic peptide, it selectively kills senescent ('zombie') cells that accumulate with age and drive inflammation.
FOXO4-DRI is a senolytic peptide, it selectively kills senescent ('zombie') cells that accumulate with age and drive inflammation. The mouse data is dramatic: improved fur, kidney function, fitness in old mice. Human data is essentially nonexistent.
Who it's for
- →Researchers studying senolytics
- →Longevity-research contexts under medical guidance
- →Educational reference, limited human safety data
What to expect
- Week 1
Mouse-model markers (improved fur density, kidney function, fitness) emerged within 10 days.
- Week 4
Off-pulse. Effects in mice persisted for weeks.
- Week 8
No human long term data exists.
Looking at FOXO4-DRI? Your next 3 steps
- 1Work out your exact dose
Vial size + BAC water turns into the exact units to draw for FOXO4-DRI.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account saves your stack; membership adds the stack-aware AI Coach.
Create free account →
How it works (mechanism)
Dominant-negative interfering peptide that disrupts the FOXO4-p53 interaction. In senescent cells, FOXO4 normally protects against p53-driven apoptosis; blocking the interaction selectively triggers death of senescent ('zombie') cells.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Active malignancy (apoptotic effects on cells in unstable states)
- ⚠Pregnancy / nursing
- ⚠Anyone risk-averse to pre-clinical-only data
Bloodwork to monitor
- • CBC and basic metabolic panel if researching
Common mistakes
- • Treating it as a longevity 'drug' (it's pre-clinical)
- • Running long cycles instead of short pulses
- • Stacking with other experimental compounds
New to FOXO4-DRI? Grab the starter checklist.
Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if FOXO4-DRI changes legal status. No account needed.
No spam. No selling your email. Just the checklist and the occasional reclassification alert.
Ask the Coach anything about FOXO4-DRI or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Get the Coach, $7.99/mo →Frequently asked
What is FOXO4-DRI?+
Is FOXO4-DRI FDA approved?+
Is FOXO4-DRI legal?+
Is FOXO4-DRI banned by WADA?+
Are you still natty after taking FOXO4-DRI?+
Do doctors prescribe FOXO4-DRI?+
What's the typical dose of FOXO4-DRI?+
What are the side effects of FOXO4-DRI?+
How long until FOXO4-DRI starts working?+
What can you stack with FOXO4-DRI?+
Where do people get FOXO4-DRI?+
More in Longevity
Studied as an anti-aging and sleep-cycle peptide. A tetrapeptide derived from epithalamin, looked at for telomerase activation and circadian / pineal support, with limited human data.
Aimed at brain aging and your body clock. A Russian-origin tripeptide (Glu-Asp-Arg) with limited human data, so treat it as experimental.
A compound studied for protecting the brain and keeping cells alive and insulin-sensitive as you age. A mitochondrial-derived peptide encoded inside mitochondrial DNA, studied for neuroprotection, insulin sensitivity, and cellular survival.
A family of short (2-4 amino acid) peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Tissue-specific organ-support peptides. Limited Western clinical data.